Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.62 |
| ▸ | KDR | P35968 | 8/20 | 0.62 |
| ▸ | LCK | P06239 | 7/20 | 0.62 |
| ▸ | TEK | Q02763 | 4/20 | 0.62 |
| ▸ | JAK3 | P52333 | 4/20 | 0.62 |
| ▸ | DDR2 | Q16832 | 5/20 | 0.61 |
| ▸ | BRAF | P15056 | 5/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 6/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | BCR | P11274 | 1/20 | 0.55 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 4/20 | 0.55 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13220047 | 0.83 | KDR (0.69) | MAPK14KDRLCKTEKJAK3 | |
| SCHEMBL13219723 | 0.82 | LCK (0.76) | MAPK14KDRLCKTEKJAK3 | |
| SCHEMBL3586277 | 0.82 | TEK (0.77) | MAPK14KDRLCKTEKDDR2 | |
| SCHEMBL13220068 | 0.82 | KDR (0.74) | MAPK14KDRLCKTEKJAK3 | |
| SCHEMBL1705565 | 0.80 | LCK (0.65) | MAPK14KDRLCKTEKJAK3 | |
| SCHEMBL13220177 | 0.80 | KDR (0.70) | MAPK14KDRLCKTEKJAK3 | |
| SCHEMBL19328015 | 0.78 | CSF1R (0.63) | MAPK14KDRLCKTEKJAK3 | |
| SCHEMBL4017741 | 0.78 | LCK (0.66) | MAPK14KDRLCKTEKJAK3 | |
| SCHEMBL5493948 | 0.78 | LCK (0.78) | MAPK14KDRLCKTEKJAK3 | |
| SCHEMBL19327934 | 0.78 | KDR (0.61) | MAPK14KDRLCKTEKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | IRAK3, IRAK1, MAP3K1 | MAPK14 613/4885KDR 666/4885LCK 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.